Modified two-sided normal tolerance intervals for batch acceptance of dose uniformity

Pharmaceutical Statistics

Volumn 3, Issue 2, 2004, Pages 89-97

  Hauck, Walter W ^a   Shaikh, Reshama ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Content uniformity; Tolerance intervals

Indexed keywords

DRUG;

ANALYTICAL ERROR; ARTICLE; DOSE RESPONSE; DRUG RESEARCH; DRUG TOLERANCE; HUMAN; MATHEMATICAL COMPUTING; SAMPLE SIZE; SIMULATION; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE;

EID: 10644295666     PISSN: 15391604     EISSN: None     Source Type: Journal    
DOI: 10.1002/pst.103     Document Type: Article

References (14)

1. Katori N, Aoyagi N, Kojima S. A proposal for revision of the content uniformity test and weight variation test. Pharmacopeial Forum 1997; 23:5325-5333.
2. PhRMA Statistics Working Group. Recommendations for a globally harmonized uniformity of dosage units test. Pharmacopeial Forum 1999; 25:8609-8624.
3. < 905 > Uniformity of dosage units (Harmonization draft). Pharmacopeial Forum 2001; 27: 2615-2619.
4. IPAC-RS. A parametric tolerance interval test for improved control of delivered dose uniformity of orally inhaled and nasal drug products. www.ipacrs.com/PDFs/IPAC-RS_DDUΡoposal.pdf, 15 November 2001.
5. Owen DB. A special case of a bivariate non-central t distribution. Biometrika 1965; 52:437-446.
6. Hauck WW, Shaikh R. Sample sizes for batch acceptance from single and multistage designs using two-sided normal tolerance intervals with specified content. Journal of Biopharmaceutical Statistics 2001; 11:335-346.
7. Odeh RE, Chou Y-M, Owen DB. Sample-size determination for two-sided β-expectation tolerance intervals for a normal distribution. Technometrics 1989; 31:461-468.
8. Center for Drug Evaluation and Research, Food and Drug Administration. Nasal spray and inhalation solution, suspension, and spray drug products - CMC documentation, 2002.
9. Olsson B. Parametric tolerance interval (PTI) test for improved control of delivered dose uniformity (DDU) in orally inhaled and nasal drug products (OINDP). Presentation to the US FDA Advisory Committee for Pharmaceutical Science, 12 March 2003. www.fda.gov/ohrms/dockets/ac/03/slides/3926S2_04_Olsson_files/frame.htm.
10. Lan KKG, DeMets LL. Discrete sequential boundaries for clinical trials. Biometrika 1983; 70: 659-663.
11. Pocock SJ. Group sequential methods in the design and analysis of clinical trials. Biometrika 1977; 64:191-199.
12. Lan KKG. The theory of group sequential methods in clinical trials. Journal of the Chinese Statistical Association 1985; 23 171-178.
13. Hauck WW, Preston PE, Bois FY. A group sequential approach to crossover trials for average bioequivalence. Journal of Biopharmaceutical Statistics 1997; 7:87-96.
14. Williams RL, Adams WP, Poochikian G, Hauck WW. Content uniformity and dose uniformity: Current approaches, statistical analyses, and presentation of an alternative approach, with special reference to oral inhalation and nasal products. Pharmaceutical Research 2002; 19:359-366.